Congratulations to the Reed and Noorchashm families and their Slay Sarcoma Foundation supporters!
Slay Sarcoma Research Initiative and Abramson Cancer Center – Penn Medicine announced partnership in funding a new uLMS research initiative. Using xenograft models of patient derived tumor in mice and Next Generation gene sequencing, they hope to identify new therapeutic targets and treatments.
Thus far, they have learned that approximately 20% of uterine leiomyosarcomas have amplification of CCNE1, which heavily rely on cell cycle checkpoint G2/M for survival. They will be testing the mice models for novel treatments targeting this checkpoint.